![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The Effect of Low-dose Ritonavir on the Pharmacokinetics of the Investigational HCV Protease Inhibitor Telaprevir in Healthy Volunteers
|
|
|
Reported by Jules Levin
CROI 2011 March 2 Boston
V Garg1, X Luo1, L McNair1*, R van Heeswijk2, and RS Kauffman1
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA ,2Tibotec BVBA, Beerse, Belgium
![apasl1.gif](../images/031411/031411-5/apasl1.gif)
![apasl2.gif](../images/031411/031411-5/apasl2.gif)
INTRODUCTION
Telaprevir (TVR), an inhibitor of the hepatitis C virus (HCV) NS3/4A protease,1,2
is being developed as a treatment for hepatitis C infection in combination with
pegylated interferon and ribavirin. In vitro studies suggested that TVR is both a
substrate and an inhibitor of CYP3A. In addition, in vivo studies in rats demonstrated
an increased plasma exposure of TVR when co-administered with ritonavir (RTV).3
The objective of this study was to evaluate the effect of low-dose RTV on the
pharmacokinetics (PK) of TVR in human volunteers.
![apasl3.gif](../images/031411/031411-5/apasl3.gif)
![apasl4.gif](../images/031411/031411-5/apasl4.gif)
![apasl5.gif](../images/031411/031411-5/apasl5.gif)
![apasl6.gif](../images/031411/031411-5/apasl6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|